成人原发免疫性血小板减少症二线药物应用

大理大学学报 ›› 2019, Vol. 4 ›› Issue (2): 44-.

成人原发免疫性血小板减少症二线药物应用

董中明，周朝阳，李培斌，杨国彪

（大理大学第四附属医院血液科，云南楚雄675000）

收稿日期:2018-03-20 修回日期:2018-12-15 出版日期:2019-02-15 发布日期:2019-02-15
作者简介:董中明，主治医师，主要从事血液病临床治疗研究.

Application of Second-line Drugs in the Treatment of Adult Primary Immune Thrombocytopenia

Dong Zhongming, Zhou Chaoyang, Li Peibin, Yang Guobiao

（Department of Hematology, The Fourth Affiliated Hospital of Dali University，Chuxiong, Yunnan 675000, China）

Received:2018-03-20 Revised:2018-12-15 Online:2019-02-15 Published:2019-02-15

摘要/Abstract

摘要： ［摘要］目的：评价对比达那唑、利妥昔单抗、重组人血小板生成素（rhTPO）等3种二线药物治疗成人原发免疫性血小板减少症
（ITP）的有效性、安全性及药物疗效之间的差异。方法：收集大理大学第四附属医院患者74例，分3组分别使用3种药物，做回
顾分析。结果：对比有效率、治疗后升高值等显示rhTPO治疗组和利妥昔单抗治疗组间差异无统计学意义（P＞0.05），此二组
与达那唑治疗组比较差异有统计学意义（P＜0.05）。结论：3种药物均有效，利妥昔单抗治疗组与TPO治疗组疗效相当且明显
优于达那唑治疗组。

关键词: ［关键词］成人原发免疫性血小板减少症, 达那唑, 利妥昔单抗, 血小板生成素

Abstract: 〔Abstract〕Objective：To evaluate the safety and efficacy of such second-line drugs as danazol, rituximab and recombinant human
thrombopoietin（rhTPO）in treating adult primary immune thrombocytopenia（ITP）. Methods：The clinical data of 74 patients with
immunological thrombocytopenia were collected. The patients were divided into three groups treated with the three drugs respectively,
and then a retrospective analysis was made. Results: There were no differences between the rhTPO group and the rituximab group（P＞
0.05）, and there were differences between the above-mentioned two groups and the danazol group（P＜0.05）. Conclusion: All the
three drugs are effective. Rituximab group and rhTPO group have the same efficacy and are significantly better than danazol group.

Key words: 〔Key words〕adult primary immune thrombocytopenia, danazol, rituximab, recombinant human thrombopoietin（rhTPO）

董中明，周朝阳，李培斌，杨国彪. 成人原发免疫性血小板减少症二线药物应用[J]. 大理大学学报, 2019, 4(2): 44-.

Dong Zhongming, Zhou Chaoyang, Li Peibin, Yang Guobiao. Application of Second-line Drugs in the Treatment of Adult Primary Immune Thrombocytopenia[J]. Journal of Dali University, 2019, 4(2): 44-.